Xinxin Si, Yaling Wang, Nianzhuang Qiu, Chenliang Qian, Bochao Yang, Hongwei Jin, Hao Wang, Xuehui Zhang and Jie Xia
RSC Med. Chem., 2025,16, 4731-4741
Abstract
We have discovered a potent DYRK1A inhibitor Y16-5 by virtual screening and in vitro biological evaluation. This compound showed strong in vitro neuroprotective activity and favorable druglikeness.
Mengyu Ren, Huanhua Chen, Zhenshu Li, Jiacheng Zhuang, Aizhu Yang, Xiangdong Li, Xinyu Li, Xinpeng Wang, Zonghe Xu, Xianghuan Liu, Jiawen Song, Tianhao Jiang, Zihua Xu, Xudong Gao and Qingchun Zhao
RSC Med. Chem., 2026, Advance Article
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by irreversible cognitive decline and memory loss.
Mihaela-Liliana Ţînţaş, Ludovic Peauger, Anaïs Barré, Cyril Papamicaël, Thierry Besson, Jana Sopkovà-de Oliveira Santos, Vincent Gembus and Vincent Levacher
RSC Med. Chem., 2024,15, 963-980
Abstract
Promising multitargets ligands in Alzheimer's disease: sequential BuChE and DYRK1A/CLK1 kinases inhibition.
Fengqiu Ma, Yan Ma, Keke Liu, Junying Gao, Shasha Li, Xiaowen Sun and Guorong Li
Food Funct., 2023,14, 1484-1497
Abstract
Schematic representation of resveratrol inducing DNA damage-mediated cancer cell senescence through the DLC1–DYRK1A–EGFR axis.
G. Rajamani, Saba Naqvi and Abha Sharma
RSC Med. Chem., 2026,17, 15-51
Abstract
Structure–activity relationships of GSK-3β inhibitors for Alzheimer's disease.